Equities researchers at UBS Group initiated coverage on shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report) in a research report issued on Friday,Benzinga reports. The firm set a “buy” rating and a $21.00 price target on the stock. UBS Group’s price objective indicates a potential upside of 37.89% from the stock’s current price.
Telix Pharmaceuticals Limited American Depositary Shares Stock Performance
Shares of NASDAQ TLX traded up $0.08 during mid-day trading on Friday, reaching $15.23. The company had a trading volume of 39,581 shares. Telix Pharmaceuticals Limited American Depositary Shares has a 52 week low of $14.81 and a 52 week high of $19.99.
See Also
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- What Are Dividends? Buy the Best Dividend Stocks
- Top-Performing Non-Leveraged ETFs This Year
- Using the MarketBeat Stock Split Calculator
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- How Investors Can Find the Best Cheap Dividend Stocks
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
